CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 133831-133947 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T86373","span":{"begin":0,"end":116},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"HYB2055 was evaluated for its safety and immunopharmacology in a phase 1 clinical trial in healthy human volunteers."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T326","span":{"begin":0,"end":116},"obj":"Sentence"}],"text":"HYB2055 was evaluated for its safety and immunopharmacology in a phase 1 clinical trial in healthy human volunteers."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1090","span":{"begin":8,"end":11},"obj":"Disease"}],"attributes":[{"id":"A1090","pred":"mondo_id","subj":"T1090","obj":"http://purl.obolibrary.org/obo/MONDO_0010518"}],"text":"HYB2055 was evaluated for its safety and immunopharmacology in a phase 1 clinical trial in healthy human volunteers."}